AVIR Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Atea Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.92 |
52 Week High | US$4.60 |
52 Week Low | US$2.77 |
Beta | 0.18 |
11 Month Change | 16.32% |
3 Month Change | 5.66% |
1 Year Change | 15.29% |
33 Year Change | -84.35% |
5 Year Change | n/a |
Change since IPO | -87.08% |
Recent News & Updates
Recent updates
Atea wins FDA Fast Track status for dengue treatment
Sep 26Atea Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
May 13Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Jan 05Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
Nov 25A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Oct 20U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs
Jun 17Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 15Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
May 13Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
Apr 08Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business
Mar 06Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares
Jan 30Shareholder Returns
AVIR | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 9.8% | -0.6% | -0.6% |
1Y | 15.3% | 17.9% | 17.3% |
Return vs Industry: AVIR underperformed the US Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: AVIR underperformed the US Market which returned 17.5% over the past year.
Price Volatility
AVIR volatility | |
---|---|
AVIR Average Weekly Movement | 6.7% |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AVIR has not had significant price volatility in the past 3 months.
Volatility Over Time: AVIR's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 74 | Jean-Pierre Sommadossi | ateapharma.com |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19.
Atea Pharmaceuticals, Inc. Fundamentals Summary
AVIR fundamental statistics | |
---|---|
Market cap | US$328.47m |
Earnings (TTM) | -US$163.66m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs AVIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AVIR income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$98.71m |
Gross Profit | -US$98.71m |
Other Expenses | US$64.95m |
Earnings | -US$163.66m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.94 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did AVIR perform over the long term?
See historical performance and comparison